Zhang Yuejiao, Zhao Ruiyi, Jiang Nan, Shi Yun, Wang Qianmi, Sheng Ye
Nursing Department, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Int J Nurs Sci. 2021 Jun 4;8(3):252-256. doi: 10.1016/j.ijnss.2021.05.005. eCollection 2021 Jul 10.
To assess whether the extension of the flushing interval will increase risks of complications associated with totally implantable venous access port (TIVAP) in the off-treatment period.
A retrospective single-center observational study was performed. Patients with a TIVAP in the off-treatment period that underwent regular flushing in our clinic were included. Data concerning patients and their TIVAPs were recorded. Patient baseline characteristics and TIVAP-related complications were analyzed. Continuous variables were analyzed by ANOVA or the Kruskal-Wallis test. To compare the occurrence of TIVAP-related complications, the chi-square test was used; if needed, Fisher's exact test was used.
Totally 607 patients were reviewed, and 563 patients were finally included. Thirteen complications were recorded, including 11 cases of catheter occlusion (1.95%), one case of port cannula rotation (0.18%), and one case of catheter tip malposition (0.18%). No device-related infection or venous thrombosis was recorded. Among these patients, the average flushing interval was 35.27 ± 13.09 days. Patients were divided into three groups according to the flushing interval: every 28 days or less (Group 1, = 133); every 29-44 days (Group 2, = 350); and every 45 days or more (Group 3, = 80). No significant difference in catheter-related complications was found among the three groups ( > 0.05).
In the TIVAP off-treatment period, patients without any history of TIVAP-related complications during approximately one year can attempt to prolong the flushing interval to more than 4 weeks; we further suggest that 5-6 weeks may be an appropriate option for these patients.
评估在非治疗期延长冲管间隔时间是否会增加完全植入式静脉输液港(TIVAP)相关并发症的风险。
进行一项回顾性单中心观察性研究。纳入在我院门诊接受定期冲管的非治疗期TIVAP患者。记录患者及其TIVAP的相关数据。分析患者基线特征和TIVAP相关并发症。连续变量采用方差分析或Kruskal-Wallis检验进行分析。为比较TIVAP相关并发症的发生率,采用卡方检验;必要时,采用Fisher精确检验。
共纳入607例患者进行评估,最终563例患者纳入研究。记录到13例并发症,包括11例导管堵塞(1.95%)、1例输液港套管旋转(0.18%)和1例导管尖端位置异常(0.18%)。未记录到与装置相关的感染或静脉血栓形成。这些患者的平均冲管间隔时间为35.27±13.09天。根据冲管间隔时间将患者分为三组:每28天或更短(第1组,=133);每29 - 44天(第2组,=350);每45天或更长(第3组,=80)。三组之间导管相关并发症无显著差异(>0.05)。
在TIVAP非治疗期,近一年无TIVAP相关并发症病史的患者可尝试将冲管间隔时间延长至4周以上;我们进一步建议5 - 6周可能是这些患者的合适选择。